Peter Martin

Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout its long history, they have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. They are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. They have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last fifteen years, they have focused on expanding its pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. They value its development partnerships as, together with its own in-house product development; they support its growth ambitions and will help to facilitate its continued business expansion. They have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, and product registration or manufacturing resources that its partners require. In the years ahead Norgine will continue to implement this successful strategy, building on its established infrastructure, strengthening its pan-European presence and collaborating with like-minded companies and organizations.

Norgine Ventures Management Ltd. acts as an alternative investment manager. The company was founded by Peter Stein in 2012 and is headquartered in Harefield, the United Kingdom.

Norgine Ltd. provides pharmaceutical services. The company is headquartered in South Wales, the United Kingdom.

Arc Medical Design Ltd. manufactures and supplies medical, dental instruments. Its products are ENDOCUFF and Wide-Eye Polyptrap. The company was founded on October 7, 2008 and is headquartered in Leeds, the Unite Kingdom.

Norgine Pharmaceuticals Ltd. develops, manufactures and markets pharmaceutical products. Its products include destolit, klean-prep, movicol, movicol chocolate, movicol paediatric chocolate, normacol, setofilm 4mg/8mg, targxan 550mg, xerotin, xifaxanta 200mg and endocuff vision. The company was founded in 1906 and is headquartered in Middlesex, the United Kingdom.

Norgine Pharmaceuticals Ltd. develops, manufactures and markets pharmaceutical products. Its products include destolit, klean-prep, movicol, movicol chocolate, movicol paediatric chocolate, normacol, setofilm 4mg/8mg, targxan 550mg, xerotin, xifaxanta 200mg and endocuff vision. The company was founded in 1906 and is headquartered in Middlesex, the United Kingdom.

Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout its long history, they have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. They are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. They have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last fifteen years, they have focused on expanding its pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. They value its development partnerships as, together with its own in-house product development; they support its growth ambitions and will help to facilitate its continued business expansion. They have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, and product registration or manufacturing resources that its partners require. In the years ahead Norgine will continue to implement this successful strategy, building on its established infrastructure, strengthening its pan-European presence and collaborating with like-minded companies and organizations.

Norgine Pharma manufactures pharmaceutical product. It offers medicines, vaccines, tablets and injection. The company is headquartered in Dreux, France.

Norgine Pharma manufactures pharmaceutical product. It offers medicines, vaccines, tablets and injection. The company is headquartered in Dreux, France.